{"id":2159,"date":"2026-06-07T07:00:00","date_gmt":"2026-06-07T07:00:00","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/06\/07\/chariotmsx\/"},"modified":"2026-06-07T07:00:00","modified_gmt":"2026-06-07T07:00:00","slug":"chariotmsx","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/06\/07\/chariotmsx\/","title":{"rendered":"ChariotMSX"},"content":{"rendered":"
Tweet<\/a><\/div>\n

ChariotMS<\/a> is coming of age. We started recruiting in July 2021, completed that in Jan 2025 and data lock for the 204 (of 200 planned) participants is in April 2027, so in less than one year. We are therefore planning ahead, thinking what success or failure would look like. Success seems quite easy to define: If we hit our primary endpoint, i.e. demonstrate significant delay in nine-hole-peg test<\/a> speed over a 2-year observation period in people taking cladribine tablets<\/a> (CladT) versus those taking placebo, it’s job done.<\/p>\n

However, there are a few reasons why an extension study would make sense:<\/p>\n

    \n
  1. Following up people with advanced MS (pwAMS) enrolled in ChariotMS over 2 (or more) after they completed the study would be in line with the current prescribing model for CladT of the NHS, i.e. two treatment cycles over 2 years, with a four-year efficacy horizon.<\/li>\n
  2. In pwAMS, it may take longer than the two years follow-up covered by ChariotMS to detect a difference between the two treatment arms. The well-characterised ChariotMS cohort provides a unique opportunity to establish efficacy after 4+ years should the core study fail to reach its primary endpoint. If ChariotMS does reach its primary endpoint, ChariotMSX will enable confirmation of duration and size of the effect after an additional 2+ years follow-up.<\/li>\n
  3. Undertaking an extension study benefits retention in ChariotMS. Many participants expressed concerns about what will happen after they have completed all their study visits. The prospect of ChariotMSX will inspire further focus and hope in this population who have for too long been neglected regarding MS disease modification.<\/li>\n
  4. Acquiring another timepoint 2+ years after completing the parent study (ChariotMS) could highlight a further increase in long-term effectiveness of CladT with pwAMS as well as overall quality of life.<\/li>\n<\/ol>\n

    We\u2019ve spent quite some time & energy on drafting ChariotMSX and came up with what discussions with statisticians and others in the team agreed is an attractive solution: A single timepoint follow-up at 4 years+ after the first tablet in the parent study (ChariotMS). This also happens to be the most cost-effective option.<\/p>\n

    Below there are 3 slides, one providing an overview of all 24 trial sites, one illustrating the current (parent) study (= ChariotMS), and the third slide showing the *single time point study* (= ChariotMSX) at 48 months, or longer if participants are already passed that milestone, we would like to collect. Participants would have to come to the hospital only once<\/strong>; informed consent would be done remotely\/electronically.<\/p>\n

    <\/object>ChariotMS_ChariotMSX<\/a>Download<\/a><\/div>\n

    I’d be keen to learn your thoughts about this. I imagine there will be quite a few, such as: Will the drug be available if the original study (ChariotMS) is positive making an Extension Study perhaps less relevant? Will people remain blinded for the study arm (CladT \/ placebo) until ChariotMSX is completed? What if people are already participating in other studies, or taking another treatment, once they have completed all ChariotMS visits?<\/p>\n

    I’m sure you have more…<\/p>\n

    We are also running a webinar around this at 6pm on the 22nd of June. If you’d like to join, please email y.robinson@qmul.ac.uk and we’ll share the MS Teams link with you.<\/strong><\/p>\n

    Disclaimer: I am the Chief Investigator of ChariotMS.<\/p>\n

    Support: ChariotMS (17\/145\/09) is funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership. The views expressed here are those of the authors and not necessarily those of the MRC, NIHR, or the Department of Health and Social Care. ChariotMS is co-funded by the MS Society UK, National MS Society (US), Barts Charity and Merck (CrossRef Funder ID:10.13039\/100009945).<\/p>\n

    Source: multiple-sclerosis-research.org<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    Tweet ChariotMS is coming of age. We started recruiting in July 2021, completed that in Jan 2025 and data lock for the 204 (of 200 planned) participants is in April 2027, so in less than one year. We are therefore planning ahead, thinking what success…<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-2159","post","type-post","status-publish","format-standard","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/2159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=2159"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/2159\/revisions"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=2159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=2159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=2159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}